# A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Source: https://onco.cc/trials/nct06717126/  
OnCo record `nct06717126` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Roginolisib in uveal melanoma, run by iOnctura, active and no longer recruiting.

## Summary

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma is a phase 2 interventional study registered as NCT06717126 by iOnctura, with 85 participants enrolled, started 2025-02-27 and due to reach its primary completion in 2027-12. Interventions recorded: roginolisib and Investigator choice of standard therapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06717126
- Phase: 2
- Setting: A Phase II, Multi-centre, Open Label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients With Advanced/Metastatic Ocular/Uveal Melanoma
- Sponsor: iOnctura
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT06717126: https://clinicaltrials.gov/study/NCT06717126

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Roginolisib](https://onco.cc/drugs/roginolisib/)
- companies: [iOnctura](https://onco.cc/companies/ionctura/)

---
JSON: https://onco.cc/api/v1/entities/nct06717126.json